NCT04653688Completed
Markers of Disease Progression and Gait Within the Parkinsonian Population
A Prospective Study on Markers of Disease Progression and Gait Within the Parkinsonian Population
Source: ClinicalTrials.gov · Last updated 4 Dec 2025
Brief summary (registry, in English)
The aim of the project is to evaluate disease progression of patients with Parkinsonian syndrome of various severity through regular home-based gait parameters analysis. We identified several steps in this project: 1. Acquisition of gait data in 120 patients with Parkinsonism at different stages in hospital and ecological condition (during 10 days at home), in a repetitive manner: 1. 30 Early PD patients, before 3 years of disease duration (MDS criteria, 2018) 2. 30 PD patients with motor fluctuations (5 to 8 years of disease duration) (MDS criteria, 2018) 3. 30 PD patients with FoG (10 years of disease duration) (MDS criteria, 2018) 4. 30 patients with MSA (less than 5 years after the first symptom) 2. Control groups will be composed by 30 healthy volunteers Correlation analysis with clinical measurements and biomarkers, namely blood biomarkers for neurodegeneration (4HN, NFLT …) and multimodal MRI repeated assessments (Iron overload, inflammation and degeneration) and genetic panel for common haplotypes involved in Parkinsonism.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 83 (actual)
- First submitted
- 6 Oct 2020
- Start date
- 22 Dec 2020
- Primary completion date
- 17 Oct 2024
- Lead sponsor
- University Hospital, Lille
- Diseases
- Parkinson disease
- NCT number
- NCT04653688
What you commit to
- Study type: Interventional
- Participants enrolled: 83
- From 22 Dec 2020 to the primary completion date, 17 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- STN DBS for PD patients
- Intraduodeno-jejunal levodopa infusion (duodopa)
- Inability to walk without aid (walker or walking stick)
Who the study is looking for
- PD Patients:
- Age: from 40 to 80 years
- Absence of intercurrent pathology that may interfere with the purpose of the study (rheumatologic or orthopedic condition, cardiac, severe pulmonary disease that may limit the perimeter of walking)
- Each group will be composed of:
- 30 PD with a disease duration \< 3 years
- 30 PD with a disease duration between 5 to 8 years
- 30 PD with a disease duration \> 10 years MSA Patients
- Age \> 30 years old
- \< 5 years of disease duration
- deemed by the physicians to be able to walk at 1 year
- Healthy subjects
- Similar age and sex distribution
- For all
- Absence of intercurrent pathology that may interfere with the purpose of the study (rheumatologic or orthopedic condition, cardiac, severe pulmonary disease that may limit the perimeter of walking)
- Absence of cognitive disorders (MoCA\> 24/30 according to the MDS criteria)
- Stable treatment for at least 2 weeks before inclusion
- Ability to walk at least 100 meters
- Have an affiliation to the social security or equivalent
- Have signed an informed consent
Age in the registry: 30 years to 80 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hopital Roger Salengro, CHU Lille Coordinator of this site? Confirm its status | Lille | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.